We continuously invest in research into new medicines for serious diseases. In 2025, Amgen invested a total of €6,3 billion globally1. Of this, €6,4 million was invested in R&D in 2025 in the Netherlands. These are expenses on non-clinical studies, clinical studies, prospective non-intervention studies, including related costs.
2025 R&D Transfer of value rapport Nederland (Update 30/06/2026)
2024 R&D Transfer of value rapport Nederland (Update 26/05/2025)
2023 R&D Transfer of value rapport Nederland (Update 03/05/2024)
2022 R&D Transfer of value rapport Nederland (Update 03/06/2023)
2021 R&D Transfer of value rapport Nederland (Update 03/06/2022)
EFPIA Disclosure Code Methodological Note (English)
Amgen EFPIA Disclosure Code Self-Certification Scheme
1Converted from US$ by XE currency converter, accessed 1 June 2026
By selecting the Yes option, leaving Amgen.nl option you understand that you are leaving the corporate page of Amgen nl and that you will be redirected to another Internet site belonging to third parties, for whose content or opinions Amgen nl is not responsible and makes no representations regarding such content or its accuracy. By selecting this option and accessing linked third party sites, you understand that you do so at your own risk.
The website to which you will be redirected may be designed exclusively for residents of a particular country or countries, as advertised on that website. As a consequence, the website to which you will be directed may contain information on pharmaceutical products or indications that are not approved in nl. If You reside in a country other than the one to which such website is directed, please contact your local Amgen affiliate for the correct information on products in your country of residence.
By selecting the Yes option, leaving Amgen.nl option you understand that you are leaving the corporate page of Amgen nl and that you will be redirected to another Internet site belonging to third parties, for whose content or opinions Amgen nl is not responsible and makes no representations regarding such content or its accuracy. By selecting this option and accessing linked third party sites, you understand that you do so at your own risk.
The website to which you will be redirected may be designed exclusively for residents of a particular country or countries, as advertised on that website. As a consequence, the website to which you will be directed may contain information on pharmaceutical products or indications that are not approved in nl. If You reside in a country other than the one to which such website is directed, please contact your local Amgen affiliate for the correct information on products in your country of residence.